- Founded in 2016 around breakthrough research from Vanderbilt University
- Company stage: pre-clinical
- Strong IP portfolio
- Rapid path to clinic and market for lead asset
Deeply experienced team in diabetes and metabolism
Meet Our Team
Will Clodfelter was most recently the CEO of Medicus Biosciences, a preclinical biotech based in San Diego. Medicus had a successful out-license of their lead asset in 4Q19. He is also the founder and Managing Director of Ponto Ventures LLC, a biotech and strategy consultancy based in San Diego, California. Will has over 20 years leadership experience working in biopharmaceutical and medical device roles ranging from startups to Fortune 50 organizations. Prior to forming Ponto he was the Director of New Product Planning at Amylin Pharmaceuticals until the corporate sale to Bristol Myers Squibb. He has previously held Corporate Strategy and Business Development roles at Eli Lilly and has been involved in numerous startups. Will has a BS in Structural Engineering from Purdue University and an MBA in Entrepreneurship and Marketing from the Indiana University Kelley School of Business.
David Parkes, PhD
Chief Scientific Officer
Dr. David Parkes has ~25 years’ experience in scientific discovery and drug development in diabetes, obesity, NAFLD/NASH and cardiovascular disease. He held senior level roles in Discovery Research and Medical Affairs at Amylin, following extensive training in globally-recognized medical research institutes including the Salk Institute. He played pivotal roles in development of exenatide, pramlintide and metreleptin, three first in class drugs for treatment of metabolic diseases. He is currently a scientific consultant for companies including Astra Zeneca, Gilead, Prosciento and Prolynx. David received his PhD in Pharmacology from the University of Melbourne, and has published ~100 articles in high-impact journals.
Alan Cherrington, PhD
Dr. Cherrington received his undergraduate degree in Biology from the University of New Brunswick and his PhD in Physiology from the University of Toronto. He currently holds the Jacquelyn A. Turner and Dr. Dorothy J.Turner Chair in Diabetes Research. Dr. Cherrington’s work over the years has defined the effects of various hormonal and neuronal factors on liver glucose metabolism. He is recognized worldwide as an authority in this area and is the recipient of multiple awards including the Banting Medal of the American Diabetes Association.
Soumitra Ghosh, PhD
Soumitra Ghosh is a co-founder of Abvance Therapeutics, Avexegen Therapeutics, and Aquros Bio, biotech start-ups focused on diabetes, GI indications and urological disorders, respectively. His experience includes senior R&D leadership positions at Amylin Pharmaceuticals, Bristol Myers Squibb and MitoKor, where he led research programs for the development of small molecule, peptide and protein-based drug candidates for the treatment of metabolic diseases and CNS disorders. He received his MS and Ph.D. degrees in Chemistry from the Indian Institute of Technology and the University of Chicago and conducted his post-doctoral work at the Rockefeller University.
Aaron Davis has 20+ years of experience in the life science industry His career has been built on identifying and communicating value to payers and providers, with considerable experience at Amylin Pharmaceuticals in diabetes and metabolic markets. As technologies have outpaced health care payment mechanisms, his passions is helping innovators developing life-saving products understand their landscape, what works for their product, what needs to be changed and how to communicate what matters to their customers.
Scientific Board of Advisors
Bruce Bode, MD
Atlanta Diabetes Associates
Clinical Associate Professor, Emory University GA
John Buse, MD
Chief, Division of Endocrinology
University of North Carolina
Steve Edelman, MD
Professor of Medicine, UCSD
Founder Taking Control Of Your Diabetes
David Maggs, MD
Becton Dickinson Technology Innovation
Fractyl Labs, Amylin, Pfizer, Parke Davis
Jeremy Hodson Pettus MD
Assistant Professor of Medicine
Division of Endocrinology
University of California, San Diego
Jay Skyler, MD
Professor of Medicine
Division of Endocrinology Diabetes & Metabolism
University of Miami
Stephen Smith, MD
Chief Scientific Officer
AdventHealth Orlando Research Services
A Smart Solution
A titratable, fixed ratio combination of two well understood and FDA approved peptides to control glycemia while mitigating the threat of hypoglycemia.